Company Overview
Company Type: Private Company
Website: ovensa.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 0.53
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Ovensa Inc., a preclinical stage biotechnology company, provides delivery technology platforms to solve pharmacokinetic challenges or to reformulate off patent drugs without modifying or denaturing them. It offers TRIOZAN, a nanomedicine delivery platform that provides a pharmaceutical polymeric loaded micro/nanocarrier for the delivery of a range of drugs in multiple barriers, including blood brain barrier, buccal, bronchial, cornea and conjunctiva, dermal, female reproductive tract, gastrointestinal tract, and nasal. The company’s platform develops bioactives for the pharmaceutical, biomedical, cosmetic, and health supplement industries. Ovensa Inc. was founded in 2012 and is based in Aurora, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Gagne, Stephane 
President, CEO & Director

Key Board Members
Name
Title
Gagne, Stephane 
President, CEO & Director
Le, Quynh-Thu 
Chair of Scientific Advisory Board
Bertrand, Nicolas 
Member of Scientific Advisory Board
De Vleeschouwer, Steven 
Member of Scientific Advisory Board
Gagnon, Jonathan 
Member of Scientific Advisory Board
Ngassam, Kathleen 
Director
Splinter, Steven 
Director
Van Betsbrugge, Jo 
Member of Scientific Advisory Board
Vincent, Mark David
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
20 Murdock Avenue | Aurora, ON | L4G 5E5 | Canada
Phone: 905-726-9933   Fax: 905-726-9933

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Anges Québec
-
Unknown
-
-
Sneakpeek Investment
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-08-2016
Jun-08-2016
Private Placement
Target
Ovensa Inc.


0.42
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-01-2021
Company Conference Presentations
Ovensa Inc. Presents at Spring 2021 Oncology Investor Conference, Apr-01-2021 01:00 PM
Mar-31-2020
Company Conference Presentations
Ovensa Inc. Presents at 2020 NYC Spring Oncology Investor Conference, Mar-31-2020 10:20 AM
Apr-11-2019
Strategic Alliances
Tetra Bio-Pharma Inc. and Ovensa Inc. Will Engage in A Collaboration to Tackle Brain Cancer
Mar-22-2019
Strategic Alliances
Ovensa Inc. Enters into Agreement with Takeda Pharmaceutical Co. Ltd
Jun-08-2016
Private Placements
Ovensa Inc. announced that it has received CAD 0.53 million in funding


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 05:44 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Sep 18, 2023 03:44 AM
Ovensa Inc.
Ovensa Inc
Reports
32
GlobalData

Sep 15, 2023 07:48 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Jun 16, 2023 07:51 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Jun 15, 2023 11:25 PM
Ovensa Inc.
Ovensa Inc
Reports
32
GlobalData

Jun 09, 2023 04:06 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Mar 17, 2023 05:48 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Mar 16, 2023 04:59 AM
Ovensa Inc.
Ovensa Inc
Reports
32
GlobalData

Mar 10, 2023 03:07 AM
Ovensa Inc.
Ovensa Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Dec 14, 2022 03:52 AM
Ovensa Inc.
Ovensa Inc
Reports
33


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Apr-11-2019
Tetra Bio-Pharma Inc. (OTCPK:TBPM.Q)
SEDAR
News Releases
43 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Gagne, Stephane 
President, CEO & Director
905-726-9933
905-726-9933

Le, Quynh-Thu 
Chair of Scientific Advisory Board
905-726-9933
905-726-9933

Bertrand, Nicolas 
Member of Scientific Advisory Board
905-726-9933
905-726-9933

De Vleeschouwer, Steven 
Member of Scientific Advisory Board
905-726-9933
905-726-9933

Gagnon, Jonathan 
Member of Scientific Advisory Board
905-726-9933
905-726-9933

Ngassam, Kathleen 
Director
905-726-9933
905-726-9933

Splinter, Steven 
Director
905-726-9933
905-726-9933

Van Betsbrugge, Jo 
Member of Scientific Advisory Board
905-726-9933
905-726-9933

Vincent, Mark David
Member of Scientific Advisory Board
(416) 863-1865
(416) 863-5161

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gagne, Stephane 
President, CEO & Director
905-726-9933
905-726-9933

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
